C-MER MEDICAL (03309) has announced that it expects to return to profitability for the fiscal year ending December 31, 2025. The company forecasts a profit attributable to owners ranging between HK$90 million and HK$110 million. This represents a significant improvement compared to the fiscal year 2024, during which the company recorded a loss attributable to owners of HK$135 million.

The anticipated increase in profit is primarily driven by several factors. Revenue is projected to see a slight increase from HK$1.913 billion in fiscal 2024 to approximately HK$1.947 billion in fiscal 2025. The company's strategy to optimize its service network and enhance operational efficiency has yielded significant results, including the closure of underperforming businesses. Furthermore, fiscal 2025 did not see any substantial impairment losses on non-current assets, unlike fiscal 2024, which recorded impairment losses of HK$198 million.